Abstract:Background and purpose: Conversion factors between dose to medium (D m,m) and dose to water (D w,w) provided by treatment planning systems that model the patient as water with variable electron density are currently based on stopping power ratios. In the current paper it will be illustrated that this conversion method is not correct. Materials and methods: Monte Carlo calculations were performed in a phantom consisting of a 2 cm bone layer surrounded by water. D w,w was obtained by modelling the bone layer as … Show more
“…Reporting dose-to-water or dose-to-medium has been discussed in TG105 report 7 and issues related to correlating patient dose distributions calculated using "correctionbased" algorithms and those calculated using MC dose algorithms for outcome studies have been further investigated and remain to be a topic of discussion. 119,120 • Correction factors should be used for specific detectors used for dose measurement to account for the effects of detector size, shape, and composition. For example, inherent chamber build-up may affect entrance dose measurements and the detector geometry may cause large angular dependence.…”
Dose calculation plays an important role in the accuracy of radiotherapy treatment planning and beam delivery. The Monte Carlo (MC) method is capable of achieving the highest accuracy in radiotherapy dose calculation and has been implemented in many commercial systems for radiotherapy treatment planning. The objective of this task group was to assist clinical physicists with the potentially complex task of acceptance testing and commissioning MC-based treatment planning systems (TPS) for photon and electron beam dose calculations. This report provides an overview on the general approach of clinical implementation and testing of MC-based TPS with a specific focus on models of clinical photon and electron beams. Different types of beam models are described including those that utilize MC simulation of the treatment head and those that rely on analytical methods and measurements. The trade-off between accuracy and efficiency in the various source-modeling approaches is discussed together with guidelines for acceptance testing of MC-based TPS from the clinical standpoint. Specific recommendations are given on methods and practical procedures to commission clinical beam models for MC-based TPS.
“…Reporting dose-to-water or dose-to-medium has been discussed in TG105 report 7 and issues related to correlating patient dose distributions calculated using "correctionbased" algorithms and those calculated using MC dose algorithms for outcome studies have been further investigated and remain to be a topic of discussion. 119,120 • Correction factors should be used for specific detectors used for dose measurement to account for the effects of detector size, shape, and composition. For example, inherent chamber build-up may affect entrance dose measurements and the detector geometry may cause large angular dependence.…”
Dose calculation plays an important role in the accuracy of radiotherapy treatment planning and beam delivery. The Monte Carlo (MC) method is capable of achieving the highest accuracy in radiotherapy dose calculation and has been implemented in many commercial systems for radiotherapy treatment planning. The objective of this task group was to assist clinical physicists with the potentially complex task of acceptance testing and commissioning MC-based treatment planning systems (TPS) for photon and electron beam dose calculations. This report provides an overview on the general approach of clinical implementation and testing of MC-based TPS with a specific focus on models of clinical photon and electron beams. Different types of beam models are described including those that utilize MC simulation of the treatment head and those that rely on analytical methods and measurements. The trade-off between accuracy and efficiency in the various source-modeling approaches is discussed together with guidelines for acceptance testing of MC-based TPS from the clinical standpoint. Specific recommendations are given on methods and practical procedures to commission clinical beam models for MC-based TPS.
“…The dosimetric accuracy of LBTE has been investigated for a range of materials and treatment geometries and techniques [6][7][8][9], the findings generally indicating improved accuracy of the LBTE algorithm over Type B algorithms. The impact of reporting to D w and D m has been discussed for lung [10][11][12], breast [13], bone [14,15] and head and neck [16][17][18]. Recommendations have also been made for reporting dose in the routine clinical setting and in clinical trials [4,19] in the context of both Monte Carlo and LBTE algorithms.…”
Background and purpose: In radiotherapy dose calculation, advanced type-B dose calculation algorithms can calculate dose to medium (D m), as opposed to Type-B algorithms which compute dose to varying densities of water (D w). We investigate the impact of D m on calculated dose and target coverage metrics in head and neck cancer patients. Methods and materials: We reviewed 27 successfully treated (disease free at two-years post-(chemo)radiotherapy) human papillomavirus-associated (HPV) oropharyngeal cancer (ONC) patients treated with IMRT. Doses were calculated with Type-B and Linear Boltzman Transport Equation (LBTE) algorithms in a commercial treatment planning system, with the treated multi-leaf collimator patterns and monitor units. Coverage for primary Gross Tumour Volume (GTVp), high dose Planning Target Volume (PTV) (PTV_High), mandible within PTV_High (Mand ∩ PTV) and PTV_High excluding bone (PTV-bone) were compared between the algorithms. Results: Dose to 95% of PTV_High with LBTE was on average 1.1 Gy/1.7% lower than with Type-B (95%CI 1.5-1.9%, p < 0.0001). This magnitude was inversely linearly correlated with the relative volume of the PTV_High containing bone (pearson r = −0.81). Dose to 98% of the GTVp was 0.9 Gy/1.3% lower with LBTE compared with Type-B (95%CI 1.1-1.5%, p < 0.05). Dose to 98% of Mand ∩ PTV was on average 3.4 Gy/5.0% lower with LBTE than with Type-B (95%CI 4.6-5.4%, p < 0.0001). Conclusion: In OPC treated with IMRT, D m results in significant reductions in dose to bone in high dose PTVs. Reported GTVp dose was reduced, but by a lower magnitude. Reduced coverage metrics should be expected for OPC patients treated with IMRT, with dose reductions limited to regions of bone.
“…). Such a simple conversion is not appropriate for media that are much different from water (e.g., bone), and this report does not attempt to address the still‐debated issue of how to handle the situations when this type of medium is of interest . Neither are we concerned with the relative accuracy of different algorithms in calculating dose in and around drastic inhomogeneities (air, lung, or bone).…”
Section: Dose‐to‐water Vs Dose‐to‐tissuementioning
confidence: 99%
“…This “1%” was the water phantom to muscle conversion factor historically used in clinical reference calibration. It was recently pointed out that the approach is more general compared to the one, which breaks down numerically for bone. Neither approach is valid at the interface of different materials, where detailed Monte Carlo calculations are necessary …”
Section: Dose‐to‐water Vs Dose‐to‐tissuementioning
Linac calibration is done in water, but patients are comprised primarily of soft tissue. Conceptually, and specified in NRG/RTOG trials, dose should be reported as dose‐to‐muscle to describe the dose to the patient. Historically, the dose‐to‐water of the linac calibration was often converted to dose‐to‐muscle for patient calculations through manual application of a 0.99 dose‐to‐water to dose‐to‐muscle correction factor, applied during the linac clinical reference calibration. However, many current treatment planning system (TPS) dose calculation algorithms approximately provide dose‐to‐muscle (tissue), making application of a manual scaling unnecessary. There is little guidance on when application of a scaling factor is appropriate, resulting in highly inconsistent application of this scaling by the community. In this report we provide guidance on the steps necessary to go from the linac absorbed dose‐to‐water calibration to dose‐to‐muscle in patient, for various commercial TPS algorithms. If the TPS does not account for the difference between dose‐to‐water and dose‐to‐muscle, then TPS reference dose scaling is warranted. We have tabulated the major vendors' TPS in terms of whether they approximate dose‐to‐muscle or calculate dose‐to‐water and recommend the correction factor required to report dose‐to‐muscle directly from the TPS algorithm. Physicists should use this report to determine the applicable correction required for specifying the reference dose in their TPS to achieve this goal and should remain attentive to possible changes to their dose calculation algorithm in the future.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.